Get the Stockscreener App
0.9244
4.59%
-0.0445
After Hours:
.95
0.0256
+2.77%
Humacyte Inc stock is traded at $0.9244, with a volume of 11.27M.
It is down -4.59% in the last 24 hours and up +2.89% over the past month.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$0.9689
Open:
$1
24h Volume:
11.27M
Relative Volume:
1.38
Market Cap:
$249.25M
Revenue:
$2.02M
Net Income/Loss:
$-97.59M
P/E Ratio:
-1.6085
EPS:
-0.5747
Net Cash Flow:
$-102.38M
1W Performance:
-14.41%
1M Performance:
+2.89%
6M Performance:
-16.72%
1Y Performance:
-60.83%
1-Day Range:
$0.9002
$1.00
1-Week Range:
$0.9002
$1.11
52-Week Range:
$0.5469
$2.82
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.9244 | 261.25M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte, Inc. (HUMA) dips more than broader market: What you should know - MSN
Piper Sandler Maintains Humacyte(HUMA.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Humacyte Inc (HUMAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Humacyte Inc (HUMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Humacyte Inc (HUMA) Institutional Confidence - TradingKey
Humacyte Inc (HUMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Humacyte Inc (HUMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Humacyte Inc (HUMA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Humacyte Inc (HUMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Humacyte Inc (HUMAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Humacyte Inc (HUMAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Humacyte Inc (HUMAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Humacyte Inc (HUMAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Humacyte Inc (HUMAW) Institutional Confidence - TradingKey
Humacyte Inc (HUMAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Humacyte Inc (HUMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Humacyte Inc (HUMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Humacyte Inc (HUMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
HUMA Maintained by TD Cowen -- Price Target Lowered to $1.25 - GuruFocus
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know - Yahoo Finance Singapore
HUMA Reiterates by BTIG -- Price Target Maintained at $2.00 - GuruFocus
Humacyte (HUMA) Barclays 28th Annual Global Healthcare Conference Summary - Quartr
Humacyte, Inc. (HUMA) surpasses market returns: Some facts worth knowing - MSN
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Humacyte (NASDAQ:HUMA) reports positive Phase 3 V012 trial results - grafa.com
Humacyte stock rises on positive dialysis trial results By Investing.com - Investing.com India
Humacyte stock rises on positive dialysis trial results - Investing.com
Fresenius updates 6.8% Humacyte (HUMA) ownership stake disclosure - Stock Titan
Humacyte’s bioengineered vessel shows benefit for women on dialysis - Investing.com UK
Humacyte’s bioengineered vessel shows benefit for women on dialysis By Investing.com - Investing.com Nigeria
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting - The Manila Times
Bioengineered blood vessel helps women on dialysis avoid catheters longer - Stock Titan
HUMA stock plunges after-hours on proposed share offering even as dialysis data impresses - MSN
Number of shareholders of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Director at Humacyte (NASDAQ: HUMA) receives 80,000 stock options grant - Stock Titan
Humacyte (HUMA) director receives 80,000 stock options at $1.08 exercise price - Stock Titan
Humacyte (HUMA) director receives 80,000 stock options at $1.08 strike price - Stock Titan
Humacyte (HUMA) CEO indirectly awarded 80,000 stock options via spouse - Stock Titan
[Form 4] Humacyte, Inc. Insider Trading Activity - Stock Titan
Humacyte (HUMA) director Keith Anthony Jones awarded 80,000 stock options at $1.08 - Stock Titan
Humacyte (HUMA) director receives grant of 80,000 stock options at $1.08 strike - Stock Titan
Director at Humacyte (NASDAQ: HUMA) granted 80,000 stock options - Stock Titan
Director at Humacyte (HUMA) receives grant of 80,000 stock options - Stock Titan
Humacyte (HUMA) director Emery N. Brown receives 80,000 stock options award - Stock Titan
H.C. Wainwright raises Humacyte stock price target on trial data - Investing.com UK
Humacyte prices $50M public offering of common stock at $1.05/share - MSN
H.C. Wainwright raises Humacyte stock price target on trial data By Investing.com - Investing.com South Africa
Humacyte Announces Proposed Public Offering to Fund Commercialization of Symvess and Pipeline Development - Minichart
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
HUMA Maintained by HC Wainwright & Co. -- Price Target Raised to $4.00 - GuruFocus
Humacyte Announces Underwritten Public Equity Offering to Fund Growth - TipRanks
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Humacyte Inc Stock (HUMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Constantino Michael T. | Director |
May 18 '26 |
Buy |
0.89 |
11,000 |
9,840 |
43,950 |
| Sander Dale A. | CFO and Chief Corp. Dev. Off |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
267,213 |
| Parikh Shamik J | Chief Medical Officer |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
272,713 |
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):